title: Comparison of symptoms, treatment, and outcomes of coronary artery disease among rheumatoid arthritis and matched subjects undergoing percutaneous coronary intervention.
abstract: OBJECTIVE
  Rheumatoid arthritis (RA) is associated with an increased prevalence of coronary artery disease (CAD). We investigated the presenting symptoms of CAD, coronary anatomy (single versus multi-vessel CAD), and treatment among a group of subjects undergoing percutaneous coronary intervention (PCI) with angioplasty and/or stenting.
  
  
  METHODS
  We evaluated a retrospective cohort of 43 RA subjects and 43 matched non-RA subjects undergoing PCI at 2 academic referral centers. RA subjects were matched to non-RA subjects on age, gender, history of coronary artery bypass grafting, date of PCI, and interventional cardiologist. We compared cardiac risk factors, presentation, treatment, and outcomes.
  
  
  RESULTS
  The mean age of the study cohort was 71 ± 10 years, and the distribution of traditional cardiac risk factors was similar in the subjects with RA compared with the matched non-RA subjects (all P values > 0.05). Seventy-four percent of subjects with RA compared with 67% of those without RA presented with an acute coronary syndrome before PCI (P = 0.48). All subjects in this cohort undergoing PCI had at least 1 stenosis in a major epicardial vessel and similar percentages of subjects with RA (44%) and without RA (40%) had multi-vessel CAD (P = 0.66). The administration of cardiac medications both at PCI and at hospital discharge was not different among subjects with RA compared with matched non-RA subjects.
  
  
  CONCLUSIONS
  Among this cohort with significant CAD undergoing PCI, clinical characteristics, presentation, severity of CAD, treatment modalities, and outcomes were similar in subjects with RA and well-matched non-RA subjects.
authors.affiliation: Division of Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA 02115, USA. sdesai5@partners.org
authors.forename: Sonali P
authors.initials: SP
authors.lastname: Desai
authors.forename: James L
authors.initials: JL
authors.lastname: Januzzi
authors.forename: Ashvin N
authors.initials: AN
authors.lastname: Pande
authors.forename: Eugene V
authors.initials: EV
authors.lastname: Pomerantsev
authors.forename: Frederic S
authors.initials: FS
authors.lastname: Resnic
authors.forename: Anne
authors.initials: A
authors.lastname: Fossel
authors.forename: Lori B
authors.initials: LB
authors.lastname: Chibnik
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Solomon
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary; D001172:Arthritis, Rheumatoid / Q000150:complications*; D001241:Aspirin / Q000627:therapeutic use; D016022:Case-Control Studies; D003324:Coronary Artery Disease / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D015607:Stents; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D005343:Fibrinolytic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006493:Heparin; D001241:Aspirin